### **PODCAST**

### First Rounders: Ted Love

Ted Love is the president and CEO of Global Blood Therapeutics. In his conversation with *Nature Biotechnology*, he discusses why his time at Haverford College was transformative, why he views Global Blood Therapeutics as a social justice company, and what might be gained from the "racial catharsis" happening in America after the police killing of George Floyd.

https://aca.st/55237e

Published online: 10 July 2020

https://doi.org/10.1038/s41587-020-0617-x



#### **PODCAST**

# Forum: CRISPR roundtable with Doudna and Liu

Jennifer Doudna and David Liu talk with Senior Editor Markus Elsner about the state of the genome-editing field and what challenges remain, especially as various therapies are now entering the clinic. https://aca.st/70c758

Published online: 14 July 2020

https://doi.org/10.1038/s41587-020-0619-8



### **RESEARCH HIGHLIGHTS**

## Papers from the literature

Selected by the *Nature Biotechnology* editors.

CRISPR-Cas $\Phi$  from huge phages is a hypercompact genome editor

Pausch, P. et al. Science https://doi.org/10.1126/science.abb1400 (2020).

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Huo, J. et al. Nat. Struct. Mol. Biol. https://doi.org/10.1038/s41594-020-0469-6 (2020).

A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing

Mok, B. Y. et al. *Nature* https://doi.org/10.1038/s41586-020-2477-4 (2020).

Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease

Schultheiß, C. et al. Immunity https://doi.org/10.1016/j.immuni.2020.06.024 (2020).

Origins and proliferative states of human oligodendrocyte precursor cells

Huang, W. et al. Cell https://doi.org/10.1016/j.cell.2020.06.027 (2020).

Follow us on Twitter @NatureBiotech #nbtHighlight